FENNEC PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
FENNEC PHARMACEUTICALS INC. (FENC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 160.00 thousand shares for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2023-11-09
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2023-09-30 was 160.00K shares, a 433.33% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2023-06-30 was 175.00K shares.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2023-03-31 was 38.00K shares, a 90.05% decline year-over-year.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-09-30 was 30.00K shares.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2017 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2023-09-30 | 160.00K shares 10-Q · filed 2023-11-09 | 335.00K shares derived: sum of 2 quarters · filed 2023-11-09 | 373.00K shares derived: sum of 3 quarters · filed 2023-11-09 | |
| 2023-06-30 | 175.00K shares 10-Q · filed 2023-11-09 | 213.00K shares derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2023-03-31 | 38.00K shares 10-Q · filed 2023-11-09 | |||
| 2022-09-30 | 30.00K shares 10-Q · filed 2022-11-14 | |||
| 2022-03-31 | 382.00K shares 10-Q · filed 2022-11-14 | |||
| 2017-12-31 | 0.00 shares 10-K · filed 2019-03-15 | |||
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2016-11-14 | 0.00 shares 10-Q · filed 2016-11-14 | |
| 2016-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-12 | 0.00 shares 10-Q · filed 2016-08-12 | ||
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-12 | |||
| 2015-06-30 | 1.00K shares 10-Q · filed 2015-08-11 | 1.00K shares derived: sum of 2 quarters · filed 2015-08-11 | ||
| 2015-03-31 | 0.00 shares 10-Q · filed 2015-08-11 | |||
| 2014-09-30 | -5.00K shares 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |